Results 91 to 100 of about 3,302 (197)

Drug Interaction Potential of Berberine Hydrochloride When Co-Administered with Tofacitinib and Filgotinib in Rats

Drug Design, Development and Therapy
Propose The co-treatment of ulcerative colitis with berberine hydrochloride (BBR), the Janus kinase(JAK) inhibitor Tofacitinib (TOFA), and Fligotinib (FIGA) is feasible and sophisticated in terms of mechanism.
Jinglong Wang, Shijia Lu, Chenxiao Zhang, Junjie Wang, Huiru Wu, Guofei Li   +5 more
semanticscholar   +1 more source

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review

Pharmaceuticals
Background/Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation and incomplete response to conventional therapies.
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung   +6 more
doaj   +1 more source

Filgotinib in cutaneous lupus: is a negative positive? [PDF]

Rheumatology, 2021
Kathryn Connelly, Eric F Morand
openaire   +2 more sources

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review

Mediterranean Journal of Rheumatology
Janus kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway is involved in pathophysiologic cascade of a notable number of rheumatic diseases. The development of JAK inhibitors has expanded treatment choices in rheumatoid arthritis (RA) with a sustained class-effect efficacy.
Skouvaklidou, Elpida, Deligeorgakis, Dimitrios, Skalkou, Anastasia, Skepastianos, Vasileios, Tsafis, Konstantinos, Papadimitriou, Evdokia, Pagkopoulou, Eleni, Avgerou, Paraskevi, Mytilinaiou, Maria G, Tzitiridou-Chatzopoulou, Maria, Kougkas, Nikolaos, Adamichou, Christina   +11 more
openaire   +2 more sources

Filgotinib bei Colitis ulcerosa: ein Review

Journal für Gastroenterologische und Hepatologische Erkrankungen
ZusammenfassungColitis ulcerosa ist eine chronisch entzündliche Darmerkrankung mit Befall des Kolons. Die häufigsten Symptome sind blutige und schleimige Durchfälle, Stuhldrang sowie abdominelle Schmerzen. Diese Symptome stellen für die Betroffenen oft eine wesentliche gesundheitliche Beeinträchtigung dar.Filgotinib ist ein Medikament, das in oraler ...
Blesl, Andreas, Novacek, Gottfried, Reinisch, Walter, Kienbauer, Melanie, Platzer, Reingard, Wolzt, Michael, Koch, Robert, Högenauer, Christoph, Ribarics, Reiner, Moschen, Alexander   +9 more
openaire   +2 more sources

Filgotinib [PDF]

, 2020
openaire   +1 more source

Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

PLoS ONE
Background Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in
M. Akiyama, Toshihiko Hidaka, M. Kaneko, Satoshi Ito, H. Taguchi, Tomonori Ishii, S. Asai, S. Hirata, Kei Ikeda, Katsuya Suzuki, Naoki Kato, Yuko Kaneko   +11 more
semanticscholar   +1 more source

Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms

Frontiers in Gastroenterology
Inflammatory bowel diseases, encompassing Crohn’s disease and ulcerative colitis, are chronic inflammatory disorders of the gastrointestinal tract. The recent expansion in advanced therapy options has not dramatically altered the ceiling of treatment ...
Faris Chater, Thomas D. Butler, Thomas D. Butler, Jimmy K. Limdi, Jimmy K. Limdi   +4 more
doaj   +1 more source

The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.

PLoS ONE
ObjectiveThis study aims to evaluate the efficacy and safety of JAK inhibitors in the treatment of patients with RA.MethodsThe databases CNKI, VIP, Wanfang, CBM, and PubMed, Embase, Cochrane Library and Web of Science were searched to identify relevant ...
Bingjia Qu, Feng Zhao, Ying Song, Junyi Zhao, Yuxin Yao, Yulan Chen, Ruobing Liao, Lingyu Fu   +7 more
doaj   +1 more source

P115 Long-term efficacy of filgotinib monotherapy and combination therapy: interim results from a post hoc analysis of the FINCH 4 study

Rheumatology
Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA). This post hoc, interim analysis of FINCH 4 (NCT03025308) characterizes the long-term efficacy of FIL administered as ...
M. Buch, P. Verschueren, R. Caporali, Thomas Huizinga, Edmund Omoruyi, D. de Vries, J. Ritsema, Francesco De Leonardis, D. Aletaha   +8 more
semanticscholar   +1 more source